Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
14 hedge funds and large institutions have $984K invested in Interpace Biosciences, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 10 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
10% more capital invested
Capital invested by funds: $894K → $984K (+$90K)
33% less funds holding
Funds holding: 21 → 14 (-7)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$184K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.2K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$39.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.39K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$510 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$478K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$91K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$38.2K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$35.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17K |
IDXG Hedge Fund Activity: Q4 2016 in Review
14 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2016, worth a combined $984K — up 10% from $894K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IDXG and 3 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $184K. The largest seller was Heartland Advisors, exiting entirely with an estimated $478K sold.
- 14 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2016, down from 21 in Q3 2016.
- Funds reported $984K of Interpace Biosciences, Inc. Common Stock stock for Q4 2016, up 10% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2016 and 10 closed out, a net change of -7 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2016 was BlackRock Institutional Trust, an estimated $184K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2016 was Heartland Advisors, an estimated $478K sold.
Based on aggregated 13F filings for Q4 2016.